2022
Intraarterial Therapies for the Management of Hepatocellular Carcinoma
Garg T, Shrigiriwar A, Habibollahi P, Cristescu M, Liddell RP, Chapiro J, Inglis P, Camacho JC, Nezami N. Intraarterial Therapies for the Management of Hepatocellular Carcinoma. Cancers 2022, 14: 3351. PMID: 35884412, PMCID: PMC9322128, DOI: 10.3390/cancers14143351.Peer-Reviewed Original ResearchDrug-eluting bead transarterial chemoembolizationHepatic artery infusionHepatocellular carcinomaTransarterial therapiesTransarterial chemoembolizationImage-guided locoregional therapiesBead transarterial chemoembolizationCatheter-based treatmentManagement of patientsLocoregional therapyBland embolizationIntraarterial therapyRadioembolization therapyEmbolic agentTherapyChemoembolizationCarcinomaEmbolizationPatientsArteryReviewInfusionTumors
2021
Lipiodol Deposition and Washout in Primary and Metastatic Liver Tumors After Chemoembolization
Nezami N, VAN Breugel JMM, Konstantinidis M, Chapiro J, Savic LJ, Miszczuk MA, Rexha I, Lin M, Hong K, Georgiades C. Lipiodol Deposition and Washout in Primary and Metastatic Liver Tumors After Chemoembolization. In Vivo 2021, 35: 3261-3270. PMID: 34697157, PMCID: PMC8627740, DOI: 10.21873/invivo.12621.Peer-Reviewed Original ResearchConceptsConventional trans-arterial chemoembolizationTrans-arterial chemoembolizationNeuroendocrine tumorsColorectal carcinomaIntrahepatic cholangiocarcinomaLipiodol depositionWashout rateContrast-enhanced magnetic resonanceMetastatic liver tumorsColorectal carcinoma tumorsLiver metastasesHepatic metastasesTumor responseTarget lesionsRetrospective analysisLiver tumorsSmall tumorsChemoembolizationCarcinoma tumorsTumorsExponential washoutCarcinomaTomography imagingWashoutCholangiocarcinoma
2020
Automated feature quantification of Lipiodol as imaging biomarker to predict therapeutic efficacy of conventional transarterial chemoembolization of liver cancer
Stark S, Wang C, Savic LJ, Letzen B, Schobert I, Miszczuk M, Murali N, Oestmann P, Gebauer B, Lin M, Duncan J, Schlachter T, Chapiro J. Automated feature quantification of Lipiodol as imaging biomarker to predict therapeutic efficacy of conventional transarterial chemoembolization of liver cancer. Scientific Reports 2020, 10: 18026. PMID: 33093524, PMCID: PMC7582153, DOI: 10.1038/s41598-020-75120-7.Peer-Reviewed Original ResearchConceptsConventional transarterial chemoembolizationLipiodol depositionTransarterial chemoembolizationLiver cancerPeripheral depositionLipiodol depositsTherapeutic efficacyNecrotic tumor areasBaseline MRITherapy optionsTumor responseTreatment responseTumor volumeLiver lesionsLipiodolH postTumor areaH-CTHounsfield unitsBiomarkersChemoembolizationHigh rateTumorsCancerImproved response
2019
Fluorodeoxyglucose PET for Monitoring Response to Embolotherapy (Transarterial Chemoembolization) in Primary and Metastatic Liver Tumors
Schobert I, Chapiro J, Pucar D, Saperstein L, Savic LJ. Fluorodeoxyglucose PET for Monitoring Response to Embolotherapy (Transarterial Chemoembolization) in Primary and Metastatic Liver Tumors. PET Clinics 2019, 14: 437-445. PMID: 31472741, DOI: 10.1016/j.cpet.2019.06.008.Peer-Reviewed Original ResearchMeSH KeywordsAgedCarcinoma, HepatocellularChemoembolization, TherapeuticFemaleFluorodeoxyglucose F18HumansInfusions, Intra-ArterialLiver NeoplasmsMagnetic Resonance ImagingMaleMiddle AgedMonitoring, PhysiologicMultimodal ImagingNeoplasm MetastasisPositron-Emission TomographyRadiopharmaceuticalsSensitivity and SpecificitySurvival AnalysisTomography, X-Ray ComputedTreatment OutcomeTumor MicroenvironmentConceptsTransarterial chemoembolizationLiver tumorsFluorine-18 fluorodeoxyglucose PETEfficacy of embolotherapyCross-sectional imaging techniquesMetastatic liver tumorsCancer cell glycolysisLocal recurrenceFluorodeoxyglucose PETTumor necrosisLiver cancerMorphologic changesCell glycolysisEmbolotherapyTumorsMonitoring responseIndividual molecular characteristicsMolecular characteristicsImaging techniquesChemoembolizationResponsePatientsRecurrencePETTherapy
2017
Diagnostic Accuracy of Split-Bolus Single-Phase Contrast-Enhanced Cone-Beam CT for the Detection of Liver Tumors before Transarterial Chemoembolization
Jonczyk M, Chapiro J, Collettini F, Geisel D, Schnapauff D, Streitparth F, Schmidt T, Hamm B, Gebauer B, Wieners G. Diagnostic Accuracy of Split-Bolus Single-Phase Contrast-Enhanced Cone-Beam CT for the Detection of Liver Tumors before Transarterial Chemoembolization. Journal Of Vascular And Interventional Radiology 2017, 28: 1378-1385. PMID: 28747271, DOI: 10.1016/j.jvir.2017.05.018.Peer-Reviewed Original ResearchConceptsTransarterial chemoembolizationHepatocellular carcinomaMR imagingCone-beam CTContrast injectionSingle-center studyContrast-enhanced MR imagingHypervascularized tumorsMore tumorsLiver tumorsHCC tumorsPhase MR imagingHepatobiliary phase MRIntraindividual comparisonTumorsChemoembolizationDiagnostic accuracyCTArterial phase MR imagingStatistical differenceWilcoxon testIndependent readersCone-beam CT imagesPatientsBetter tumor detection
2015
Feasibility of a Modified Cone-Beam CT Rotation Trajectory to Improve Liver Periphery Visualization during Transarterial Chemoembolization.
Schernthaner RE, Chapiro J, Sahu S, Withagen P, Duran R, Sohn JH, Radaelli A, van der Bom IM, Geschwind JF, Lin M. Feasibility of a Modified Cone-Beam CT Rotation Trajectory to Improve Liver Periphery Visualization during Transarterial Chemoembolization. Radiology 2015, 277: 833-41. PMID: 26000642, PMCID: PMC4654716, DOI: 10.1148/radiol.2015142821.Peer-Reviewed Original ResearchConceptsCone-beam CTTransarterial chemoembolizationLiver volumeRadiation exposureInstitutional review board-approved studyPeripheral hepatic tumorsSecondary liver cancerCT radiation exposureCone beam CT examinationsBoard-approved studyTumor detectabilityRadiation exposure reductionHepatic tumorsCT examinationsLiver cancerCT protocolPatientsCone beamMagnetic resonance imagesCT indicesC-arm rotatesCTTumorsExposure reductionRank test
2014
Assessing tumor response after loco-regional liver cancer therapies: the role of 3D MRI
Chapiro J, Lin M, Duran R, Schernthaner RE, Geschwind JF. Assessing tumor response after loco-regional liver cancer therapies: the role of 3D MRI. Expert Review Of Anticancer Therapy 2014, 15: 199-205. PMID: 25371052, PMCID: PMC4304995, DOI: 10.1586/14737140.2015.978861.Peer-Reviewed Original ResearchConceptsTumor responseResponse Evaluation CriteriaTumor response criteriaMajor clinical interestLiver cancer therapyLiver cancer lesionsClinical evidenceIntraarterial therapyCancer lesionsSolid tumorsResponse criteriaAnatomic methodsClinical interestImaging modalitiesCancer therapyTumor analysisTherapyMRILesionsTumors